Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 255,543,712
  • Shares Outstanding, K 2,529,635
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • EBIT $ 14,160 M
  • EBITDA $ 18,032 M
  • 60-Month Beta 0.39
  • Price/Sales 4.07
  • Price/Cash Flow 32.78
  • Price/Book 5.67

Options Overview Details

View History
  • Implied Volatility 28.64% ( +2.68%)
  • Historical Volatility 20.06%
  • IV Percentile 96%
  • IV Rank 88.96%
  • IV High 30.32% on 10/28/24
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.55
  • Today's Volume 12,450
  • Volume Avg (30-Day) 25,965
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 401,512
  • Open Int (30-Day) 400,145

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.80
  • Number of Estimates 6
  • High Estimate 1.90
  • Low Estimate 1.63
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +5,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.82 +1.70%
on 12/19/24
105.07 -5.32%
on 12/09/24
-3.61 (-3.50%)
since 12/06/24
3-Month
94.48 +5.29%
on 11/15/24
111.58 -10.84%
on 10/15/24
-9.04 (-8.33%)
since 10/08/24
52-Week
94.48 +5.29%
on 11/15/24
134.63 -26.11%
on 06/25/24
-17.90 (-15.25%)
since 01/08/24

Most Recent Stories

More News
When Should Investors Rotate from the Magnificent 7 To Dividend Growth?

The stock market’s bullish sentiment for the magnificent seven stocks may weaken anytime. When ...

MRK : 99.64 (-1.37%)
GD : 260.64 (+0.38%)
PFE : 26.85 (-1.03%)
BMY : 56.50 (-1.12%)
Why Viking Therapeutics Stock Plummeted by 24% in December

Viking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a rival's aggressive...

VKTX : 40.79 (-2.09%)
MRK : 99.64 (-1.37%)
LLY : 784.10 (+1.40%)
Should You Buy the Dip on This High-Flying Stock?

It's been an excellent year for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech company. Thanks to impressive mid-stage clinical results, its stock skyrocketed in February. And although it's down...

VKTX : 40.79 (-2.09%)
MRK : 99.64 (-1.37%)
Merck Stock In Focus After Regulatory Approval For PAH Drug: Retail Sentiment Brightens

The drug, Winrevair, is used for the treatment of pulmonary arterial hypertension-related conditions.

MRK : 99.64 (-1.37%)
IVV : 591.51 (-0.01%)
IWF : 404.57 (+0.19%)
2 High-Yield Dividend Stocks to Buy Early in 2025

The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (NYSE: BMY) and Merck & Co. (NYSE: MRK) stand out for their combination...

MRK : 99.64 (-1.37%)
BMY : 56.50 (-1.12%)
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move...

NVDA : 140.33 (+0.14%)
NVO : 85.35 (+2.41%)
MRK : 99.64 (-1.37%)
LLY : 784.10 (+1.40%)
NVS : 99.58 (+0.61%)
GS : 577.39 (-0.47%)
WMT : 91.49 (+0.75%)
3 Stocks That Could Be Monster Winners in 2025

What do many kids like most about the coming of a new year? The fireworks. Investors don't mind seeing some fireworks in their portfolios with a new year starting, either.

VKTX : 40.79 (-2.09%)
NVO : 85.35 (+2.41%)
MRK : 99.64 (-1.37%)
SMMT : 18.51 (+1.93%)
Selling Covered Calls On The Dogs Of The Dow Stocks

The Dogs of the Dow is a long standing wall street strategy for investing in the stock market that involves purchasing the 10 highest yielding Dow Jones stocks.

VZ : 38.79 (-0.33%)
CVX : 149.95 (+0.24%)
KO : 61.33 (+0.81%)
JNJ : 141.69 (-3.10%)
MRK : 99.64 (-1.37%)
$IUXX : 21,114.15 (-0.28%)
MCD : 287.34 (-0.69%)
QQQ : 515.16 (unch)
CSCO : 59.07 (+0.24%)
IBM : 222.94 (-0.46%)
PG : 161.47 (+0.11%)
$DOWI : 42,514.27 (-0.03%)
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing authorization application (MAA) for their antibody-drug conjugate (ADC), datopotamab...

AZN : 66.51 (-0.20%)
MRK : 99.64 (-1.37%)
PFE : 26.85 (-1.03%)
2 Reasons to Sell Merck Stock and 1 Reason to Buy

There is plenty to like about Merck (NYSE: MRK) . It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates consistent...

MRK : 99.64 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 105.56
2nd Resistance Point 104.27
1st Resistance Point 102.64
Last Price 99.83
1st Support Level 99.72
2nd Support Level 98.43
3rd Support Level 96.80

See More

52-Week High 134.63
Fibonacci 61.8% 119.29
Fibonacci 50% 114.56
Fibonacci 38.2% 109.82
Last Price 99.83
52-Week Low 94.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar